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OBJECTIVE — Risks of end-stage renal disease and premature death in patients with type 1
diabetes have declined over the past decades. Data on the survival of patients receiving renal
replacement therapy (RRT) are, however, limited. We investigated whether survival of patients
with type 1 diabetes receiving RRT has improved over time and whether improvement can be
attributable to progress in dialysis treatment or diabetes care.
RESEARCH DESIGN AND METHODS — An incident cohort of all patients with type
1 diabetes (n  1,604) starting chronic RRT in Finland between 1980 and 2005 were followed
until death or end of follow-up on 31 December 2007. The control group (n  1,556) consisted
of patients with glomerulonephritis who started RRT. All patients were identiﬁed from the
Finnish Registry for Kidney Diseases.
RESULTS — Median survival time of patients with type 1 diabetes increased progressively
from 3.60 years during 1980–1984 to 8 years in 2000–2005. In 2000–2005, the unadjusted
relative risk of death was 0.55 compared with 1980–1984. After adjustment for the most
important variables, the corresponding relative risk of death was only 0.23. For patients with
glomerulonephritis, the adjusted relative risk decreased to a lesser extent to 0.30 (P  0.007).
CONCLUSIONS — Survival of patients with type 1 diabetes and end-stage renal disease has
improved since the 1980s despite a conspicuous increase in the age of patients who start RRT,
suggesting not only true progress in dialysis therapy and overall treatment of patients with
end-stage renal disease but possibly also improved management of diabetes.
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D
iabetes is the most important cause
ofend-stagerenaldisease(ESRD)in
industrialized countries, reﬂecting
the rapidly growing number of patients
with adult-onset diabetes (1,2). The inci-
dence of type 1 diabetes, however, varies
signiﬁcantly among countries and is the
highest in the world in Finland (3). At the
end of 2007, the incidence and preva-
lenceofESRDduetotype1diabeteswere
13 and 128 per million inhabitants, re-
spectively (4). The latter accounts for
17.2% of patients receiving chronic dial-
ysis. In a recent Finnish study, the risk of
ESRDinpatientswithtype1diabeteswas
2.2% after 20 years and 7.8% after 30
years from the diagnosis of diabetes (5).
In addition, the risk had decreased over
the past decades, which is in line with the
declining incidence observed in many
other countries (6).
A European study with data from 10
national registries showed a decrease in
the mortality rates of patients with type 1
diabetesreceivingrenalreplacementther-
apy (RRT) during the time period 1991–
2000 (7). In a Danish registry study that
covered the time period 1990–2005, the
overall survival rate of patients with dia-
betes receiving RRT had improved by
15%per5calendaryears,butthesurvival
rate of patients with type 1 diabetes was
not assessed separately per time period
(8). Moreover, registry data from Austra-
lia and New Zealand from 1991 to 2005
showed no signiﬁcant change in the sur-
vival of patients with type 1 diabetes re-
ceiving RRT over time, although the
survivalofpatientswithtype2diabetesas
wellasofthatofpatientswithoutdiabetes
had improved (9). The authors also re-
ported that the prognosis of patients with
type 1 diabetes remained poor regardless
of good access to kidney transplantation.
Taken together, despite continuous ad-
vancesinthemanagementofdiabetesand
the prevention of diabetic nephropathy,
there are only scarce data on whether the
prognosis of patients with type 1 diabetes
receiving RRT has improved.
Our aim was, therefore, to investigate
whether the survival of patients with type
1 diabetes receiving RRT has improved.
We used comprehensive data for all pa-
tients with type 1 diabetes who had
startedchronicRRTinFinlandduringthe
timeperiod1980–2005,whichenableda
considerably longer follow-up period
than that in previously published studies.
RESEARCH DESIGN AND
METHODS— Our incident cohort
study included all patients with type 1
diabetes as the cause of renal failure who
had started chronic RRT (hemodialysis,
peritonealdialysis,orkidneytransplanta-
tion) in Finland from 1 January 1980 to
31 December 2005 (n  1,604). The pa-
tients were followed from the day of the
ﬁrst dialysis treatment until death or the
endofthefollow-upperiodon31Decem-
ber2007oruntilrecoveryofkidneyfunc-
tion or the patients had moved abroad or
were lost to follow-up. As a control group
we included all patients with chronic glo-
merulonephritis who had started RRT
during the same time period (n  1,556).
The control group was chosen to repre-
sent a primary renal disease and hereby
obtain information that could separate
the impact of development of RRT and
diabetes care. Patients with glomerulone-
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Helsinki University Central Hospital, Division of Nephrology, Helsinki, Finland; the
2Helsinki
UniversityCentralHospital,DepartmentofMedicine,Helsinki,Finland;the
3FinnishRegistryforKidney
Diseases, Helsinki, Finland; and the
4School of Public Health, University of Tampere, Tampere, Finland.
Corresponding author: Mikko Haapio, mikko.haapio@hus.ﬁ.
Received 7 January 2010 and accepted 21 April 2010. Published ahead of print at http://care.
diabetesjournals.org on 30 April 2010. DOI: 10.2337/dc10-0030.
The sponsors had no role in the design and conduct of the study; collection, management, analysis, and
interpretation of the data; or preparation, review, and approval of the manuscript.
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Clinical Care/Education/Nutrition/Psychosocial Research
ORIGINAL ARTICLE
1718 DIABETES CARE, VOLUME 33, NUMBER 8, AUGUST 2010 care.diabetesjournals.orgphritis caused by systemic diseases were
excluded.
We used data from the Finnish Reg-
istry for Kidney Diseases, which has an
estimated 97% coverage of all Finnish pa-
tients receiving chronic RRT since 1965.
Kidney disease diagnoses have been
stored as ICD-9 and later as ICD-10
codes, which enable separation between
type 1 and 2 diabetic nephropathy. The
registry is maintained by the Finnish Kid-
ney and Liver Association, which is fully
ﬁnanced by the Finnish government. All
patients provided written informed con-
sent and permission to use the data anon-
ymously in registry reports and for
research purposes.
Dataextractedforthisstudyincluded
informationondemographicsandpatient
characteristics: age, sex, cause of ESRD,
mode of initial RRT (hemodialysis, peri-
toneal dialysis, or kidney transplanta-
tion), information on subsequent
kidney transplantation, and cause of
death (Table 1).
ThediagnosisofESRDwasconﬁrmed
by kidney biopsy in 80 of the 1,604 pa-
tients with type 1 diabetes (5%) and a
minimum of 980 of the 1,556 patients
with glomerulonephritis (63%). In the
glomerulonephritis group, at least 43%
had the diagnosis based on biopsy during
1980–1994 and during 1995–2005 the
biopsy incidence was 73–85%, resulting
in overall biopsy percentage of at least
63%. A widely accepted clinical practice
is to avoid kidney biopsy in patients with
type 1 diabetes if there are other signs of
microvascularend-organdamage,suchas
diabetic retinopathy.
A total of 8,719 patients started RRT
and of these 18.4% (n  1,604) had type
1 diabetes and 17.8% (n  1,556) had
glomerulonephritis as the cause of ESRD.
The study period was divided into ﬁve
intervals: 1980–1984, 1985–1989,
1990–1994, 1995–1999, and 2000–
2005. Table 1 describes the study popu-
lation within these time periods. We
further divided the patients into four age-
groups based on the age at the start of
RRT: 35 years (444 patients), from 35
to 44 years (586 patients), from 45 to 54
years (383 patients), and 55 years (191
patients). A total of six patients with type
1 diabetes and 19 with glomerulonephri-
tis had a kidney transplant as the primary
treatment. The majority of these preemp-
tive transplantations took place during
1980 to 1984.
Statistical methods
Comparisons between groups were per-
formed using the 
2 test for categorical
variables. We calculated survival proba-
bilities with the Kaplan-Meier method,
withdeathastheevent,andpatientswere
censored at 31 December 2007 or at the
date of last follow-up. Median survival
times were estimated from the Kaplan-
Meier curves, and differences in survival
probabilities between groups were as-
sessed using the log-rank test. We used
Cox proportional hazards regression to
perform multivariable modeling of sur-
vival probabilities. Two-sided P  0.05
was considered statistically signiﬁcant.
For statistical analyses we used SPSS
(version 16.0). All possible ﬁrst- and sec-
ond-degree interactions between the ex-
planatory variables were considered in
the Cox model building.
RESULTS
Descriptive results
The patients with type 1 diabetes showed
a signiﬁcant increase in median age and
an overall decrease in peritoneal dialysis
mode.TheinitialRRTmodewashemodi-
alysis in 46.1%, peritoneal dialysis in
53.5%, and kidney transplantation (pre-
emptive) in 0.4%. Sex distribution re-
mained the same with two-thirds being
men. The probability to receive a kidney
transplant within 2 years from the RRT
startdiminishedfrom60%in1980–1984
to 35% in 2000–2005 (Table 1).
Table 1—Demographic data and characteristics of patients according to patient group (type 1 diabetes or glomerulonephritis) and the start
period of RRT
Patient group
Start period of RRT
All P value* 1980–1984 1985–1989 1990–1994 1995–1999 2000–2005
Type 1 diabetes
Median age (years)† 34.8 38.5 39.4 43.3 44.6 42.3 0.001
55 years (%) 2 5 12 15 18 11.9 0.001
Male sex (%) 64 67 57 66 65 63.8 0.108
Peritoneal dialysis (%)† 55 66 55 49 48 53.5 0.001
Kidney transplantation within 2 years (%)‡ 60 52 47 40 35 44.6 0.001
Cause of death (%)
Cardiovascular 62 67 66 64 71 65.8 0.425
Infection 18 18 17 19 13 17.1 0.631
n 205 281 317 361 440 1,604
Glomerulonephritis
Median age (years)† 43.5 48.9 55.3 56.5 57.2 53.1 0.001
55 years (%) 26 34 50 52 55 45.2 0.001
Male sex (%) 70 71 71 72 74 71.8 0.824
Peritoneal dialysis (%)† 29 40 41 34 27 33.9 0.001
Kidney transplantation within 2 years (%)‡ 76 60 46 43 38 50.4 0.001
Cause of death (%)
Cardiovascular 49 50 55 47 44 49.5 0.424
Infection 27 25 17 25 23 23.3 0.217
n 242 276 304 338 396 1,556
Data are median or %. *P value for the overall signiﬁcance between the groups of RRT start periods. †At the start of RRT. ‡From the start of RRT.
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Of the 1,604 patients with type 1 diabe-
tes, 1,047 (65.3%) had died, and 557 pa-
tients were censored (alive at the end of
follow-up on 31 December 2007, n 
548; regained own kidney function, n 
5; moved abroad, n  4; and lost to fol-
low-up, n  0). Cardiovascular causes re-
mained the main cause of death and
comprised65.8%ofdeaths(Table1).Me-
dian survival time increased throughout
the span of our study, from 3.60 years
(95% CI 2.50–4.70) to 7.24 (95% CI
5.74–8.74) from the time period 1980–
1984 to 1995–1999 (Fig. 1). Median sur-
vival time of patients starting RRT during
2000–2005 could not be calculated be-
cause it was longer than the maximal fol-
low-up time, thus indicating a median
survival time of 8 years. The median
survival times increased signiﬁcantly in
alloftheage-groups(Fig.2).Theabsolute
risk of death within 5 years from the start
ofRRTdroppedfrom51%in1980–1984
to 33% in 2000–2005. The unadjusted
relative risk (RR) of death was 0.55 for
patients that entered RRT in 2000–2005
compared with those that entered in
1980–1984 (Table 2). In the different
age-groups the corresponding RRs were
even lower, varying between 0.31 and
0.38, indicating a confounding effect of
age. In univariate analysis, the risk of
death increased by 4.1% (95% CI 3.4–
4.7%) per year of age at the start of RRT.
Sex was not associated with risk of death
(P  0.360). Patients having hemodialy-
sisastheinitialmodeofRRThad1.4-fold
risk (95% CI 1.2–1.6) of death compared
with patients that entered peritoneal dial-
ysis. Death risk was much higher in pa-
tients who did not receive a kidney
transplantwithin2years(RR4.0[95%CI
3.5–4.6]).
Adjusted survival of patients with
type 1 diabetes
Adjustment for age and sex revealed a
more substantial improvement in the
prognosis, with RR of death of 0.33 for
patients with type 1 diabetes starting RRT
in 2000–2005 compared with 1980–
1984. After further adjustment for initial
modeofdialysisandhavingornothaving
received a kidney transplant within 2
years from the start of RRT, the RR of
death dropped even more prominently
to 0.23 (Table 2). The risk of death
decreased, however, both in patients
who received a kidney transplant and in
those who did not (RR 0.20 [95% CI
0.11–0.37] and 0.25 [0.19–0.33],
respectively).
Interaction analysis
In the type 1 diabetic group we observed
nostatisticallysigniﬁcantﬁrst-orsecond-
degree interactions between the variables
RRT start period, age at start of RRT, sex,
initial mode of dialysis, and having or not
having received a kidney transplant
within 2 years from the RRT start.
Comparison between patients with
type 1 diabetes and
glomerulonephritis
Of the 1,556 patients with glomerulone-
phritis, 823 (52.9%) had died and 733
were censored (alive on 31 December
2007, n  719; regained own kidney
function, n  8; moved abroad, n  4;
and lost to follow-up, n  2). The initial
RRT mode was hemodialysis in 64.8%,
peritoneal dialysis in 33.9%, and kidney
transplantation (preemptive) in 1.2%.
Median survival time of patients with glo-
merulonephritis was signiﬁcantly higher
than that of patients with type 1 diabetes
but did not show any signiﬁcant increase
during the follow-up (11.50 years on av-
erage). The unadjusted RR of death was
0.88 in patients starting RRT in 2000–
2005 compared with 1980–1984. With
adjustmentforothervariables,theRRwas
0.30, indicating a clear improvement of
prognosis also in the glomerulonephritis
group (Table 2). The risk of death de-
creased more among patients with type 1
diabetes than among patients with glo-
merulonephritis(P0.007),asindicated
by interaction analysis between diagnos-
tic group (type 1 diabetes and glomerulo-
nephritis) and the RRT start period with
adjustment for age, sex, treatment mode,
and kidney transplant status at 2 years.
During 1980–1984, the risk of death for
patients with type 1 diabetes receiving
RRT was 3.5-fold compared with patients
with glomerulonephritis, but the risk de-
creased to be only 2.7-fold during
2000–2005.
CONCLUSIONS — We observed a
considerably improved prognosis of pa-
tients with type 1 diabetes receiving RRT
since 1980. The RR of death was 77%
lower for patients beginning RRT in
2000–2005 compared with 1980–1984.
Our results are based on a nationwide da-
tabase with long-term coverage of all di-
alysis and kidney transplant patients in
Finland. To our knowledge, our study is
the ﬁrst to show improvement in the
prognosis of patients with type 1 diabetes
receiving RRT during a follow-up as long
as 28 years.
Interestingly, our study shows a pro-
gressive increase in median survival time
of patients with type 1 diabetes receiving
Figure1—Survivalprobabilityoftype1diabeticpatientsbeginningRRTaccordingtostartperiod
of RRT. Dashed lines denote cut points for median survival times.
Survival of patients with type 1 diabetes on RRT
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with similar survival improvement across
all age-groups and throughout the fol-
low-up period 1980–2007 (Fig. 2). Our
results are in line with the observations of
Sørensen et al. (8), who found that the
overallsurvivalrateofESRDpatientswith
type1ortype2diabeteshadimprovedby
15% per 5 calendar years. Our ﬁndings
are also in accordance with an earlier Eu-
ropean study by van Dijk et al. (7) that
included a larger number of patients with
ESRD but had a markedly shorter fol-
low-up time, in which there was only a
modestage-andsex-adjusted2-yearmor-
talityreductionforallpatientswithtype1
diabetes,butamorepronounced49%re-
duction in those patients that received a
kidneytransplantcomparingyears1991–
1994to1995–1998.Ourstudy,however,
is the ﬁrst focusing only on patients with
type 1 diabetes and expanding the obser-
vation period to almost three decades.
It is noteworthy that the prognosis in
this cohort improved over time despite
the fact that some patient characteristics
were changing in a direction that should
be unfavorable with regard to prognosis.
In particular, the median age of patients
with type 1 diabetes increased by nearly
10 years over the duration of our study
period,andtheglomerulonephritisgroup
aged to an even greater extent. The pro-
portion of elderly subjects increased in
both groups. Mean age of patients at the
time of type 1 diabetes diagnosis, how-
ever,hasnotchanged,butthetimebefore
development of ESRD has increased (5).
We also observed a diminishing propor-
tion of patients starting peritoneal dialy-
sis, which is the treatment mode that
correlated with the better prognosis.
Moreover, the probability of receiving a
kidney transplant declined clearly. Thus,
theimprovedprognosiscouldpossiblybe
explained by better overall management
of the patients with chronic kidney dis-
ease before and during RRT, as well as by
developments in dialysis techniques and
diabetes care.
During the follow-up time of our
study, the number of patients with type 1
diabetes starting RRT in Finland has in-
creasedfrom205in1980–1984to440in
2000–2005. Their relative proportion,
however, out of all patients starting RRT
has decreased progressively from 22 to
15%. Despite the decreasing relative inci-
dence, the relative prevalence of patients
with type 1 diabetes of all patients receiv-
Figure 2—Survival probability of patients with type 1 diabetes beginning RRT according to start period of RRT and age at start of RRT. Survival
probabilities were statistically signiﬁcantly different between start year periods in all age-groups (P  0.005).
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This conﬁrms the improved survival of
patients with type 1 diabetes receiving
RRT as shown in our current study.
To estimate the possible effect of
progress in diabetes care, we chose pa-
tientswithglomerulonephritisasthecon-
trol group because it is obvious that
among patients with glomerulonephritis
an improved prognosis could not be
caused by better diabetes care. Further-
more,weexcludedpatientswithsystemic
glomerulonephritisbecausetheycouldbe
regarded as potentially sicker than pa-
tients with disease affecting only the kid-
neys. We found a more substantial
survival beneﬁt over time for patients
with type 1 diabetes compared with pa-
tientswithglomerulonephritis,indicating
that advances in diabetes care and man-
agement of diabetes complications may
have partly contributed to our observa-
tion of improved prognosis of patients
with type 1 diabetes.
Over the last few decades, manage-
ment of diabetes has evolved remarkably
in terms of insulin regimens and more in-
tensive blood glucose monitoring. Dis-
posable insulin syringes became widely
available in the early 1970s, and home
glucose monitoring and semisynthetic
and synthetic human insulin reached
wider use in the 1980s. With the emer-
gence of multiple insulin injections in the
1990s followed by the development of
rapid-acting insulin regimens, patients
withtype1diabeteswereabletomaintain
more stable blood glucose control and
closer-to-target A1C levels. In our study
population,however,thelevelofA1Chas
shownonlyslightchangesduringthepast
years: the mean value was 8.4% in 1992
(when these data were routinely gathered
fortheﬁrsttime)andwasalmostthesame
in2007(8.0%).Nevertheless,thisﬁnding
doesnotexcludeotherpotentialimprove-
ments such as fewer hypo- and hypergly-
cemic events, with probable beneﬁcial
effects on mortality. By taking into ac-
counttheobviousdevelopmentsindiabe-
tes care, it is likely that the level of A1C
was higher in the 1980s, thus increasing
the likelihood of a negative outcome in
these patients.
On the other hand, quality and dose
of dialysis therapy have also improved
overtheyears.Duringthe1980smosthe-
modialysis patients were treated with ba-
sic techniques and low-ﬂux cellulosic
dialyzers, with no access to on-line
hemodiaﬁltration or modern synthetic
high-ﬂux dialyzers with better biocom-
patibility. Use of these has been expand-
ing since the mid-1990s, allowing
enhanced uremic toxin clearance and
ﬂexibility of hemodialysis treatment.
With peritoneal dialysis therapy, the
present availability of biocompatible ﬂu-
ids with better tolerability and solute re-
moval and icodextrin-containing ﬂuid
(with superior ultraﬁltration capability
without excess glucose load) has in-
creased the efﬁcacy of peritoneal dialysis.
In addition, the number of patients re-
ceiving peritoneal dialysis using auto-
mated overnight peritoneal dialysis
machines has increased, leading to 1)
greater toxin clearance, 2) better adjust-
mentofperitonealdialysistoeverydaylife
with improved adherence and overall pa-
tient compliance to therapy, and 3) pos-
sibly diminished peritonitis episodes
(10,11). In our patient population with
type 1 diabetes, the mean number of
weekly hemodialysis sessions increased
from 2.9 (95% CI 2.8–3.0) to 3.1 (95%
CI 3.0–3.3) from 1992 to 2007, with
mean weekly treatment hours rising from
11.4 (95% CI 10.9–12.0) to 13.5 (95%
CI 12.8–14.2). During the same time the
percentage of those patients with type 1
diabetes who entered peritoneal dialysis
therapy and initially used an automated
machine rose from 2 to 27. It is a well-
known fact that achieving target uremic
toxin clearance improves survival in pa-
tients receiving dialysis (12), and thus the
increase in dialysis dose could have led to
improved survival in our study popula-
tion. The dialysis dose, however, was
approximately the same both for the pa-
tients with type 1 diabetes and patients
with glomerulonephritis, suggesting that
anysurvivaladvantagerelatedtoprogress
indialysistechnologyshouldbesimilarin
both groups.
It could also be speculated that pa-
tients with type 1 diabetic nephropathy
are in more intensive monitoring by
health care professionals compared with
patients without diabetes. Patients with
type 1 diabetes are closely followed up
from childhood with routine visits to the
health care system, which probably have
preventive effects on cardiovascular com-
plications (13). The comprehensive man-
agement of patients approaching ESRD
includes control of blood pressure and
calcium-phosphorus level and treatment
with erythropoiesis-stimulating agents,
which are known to have an effect on car-
diovascular outcomes (14). However, in
acknowledging that 66% of those pa-
Table 2—RR of death according to the start period of RRT among patients with type 1 diabetes and patients with glomerulonephritis
RRT start period
Risk of death within
5 years of RRT start Unadjusted RR Adjusted RR* Adjusted RR†
Type 1 diabetes (n  1,604)
1980–1984‡ 0.51 (0.51–0.64) 1 1 1
1985–1989 0.45 (0.45–0.57) 0.87 (0.72–1.06) 0.72 (0.59–0.87) 0.64 (0.52–0.77)
1990–1994 0.41 (0.41–0.52) 0.70 (0.58–0.85) 0.53 (0.44–0.65) 0.44 (0.36–0.54)
1995–1999 0.38 (0.38–0.48) 0.66 (0.54–0.81) 0.43 (0.35–0.52) 0.33 (0.27–0.41)
2000–2005 0.33 (0.33–0.43) 0.55 (0.44–0.68) 0.33 (0.26–0.41) 0.23 (0.19–0.29)
Glomerulonephritis (n  1,556)
1980–1984‡ 0.23 (0.23–0.35) 1 1 1
1985–1989 0.25 (0.25–0.36) 1.01 (0.82–1.25) 0.86 (0.69–1.06) 0.76 (0.61–0.94)
1990–1994 0.33 (0.33–0.44) 1.21 (0.98–1.50) 0.72 (0.58–0.90) 0.60 (0.48–0.75)
1995–1999 0.31 (0.31–0.41) 1.17 (0.93–1.46) 0.59 (0.47–0.74) 0.49 (0.38–0.62)
2000–2005 0.23 (0.23–0.33) 0.88 (0.68–1.14) 0.37 (0.28–0.49) 0.30 (0.23–0.40)
Data are RR (95% CI). *Adjusted for age at the start of RRT, and sex. †Adjusted for age at the start of RRT, sex, initial mode of dialysis, and having or not having
received a kidney transplant within 2 years of the RRT start. ‡Reference group.
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during our study period died of cardio-
vascular causes, there is a need for further
studies to explore how comorbidities and
other related factors before and during
ESRD inﬂuence the outcome of patients
receiving RRT.
Ourstudyhassomelimitations.First,
the results might not be generalizable to
other countries, as the incidence of type 1
diabetesisamongthehighestintheworld
inFinland.Therefore,muchattentionhas
been focused on improving quality of di-
abetescare,whichmayexplainpartofthe
favorable progress in prognosis of the
Finnish patients. Second, for most of
the patients with type 1 diabetes we did
not have kidney biopsy conﬁrmation of
thediagnosisbecausethelong-termprac-
tice in Finland is to perform a biopsy only
in rare patients when other microvascu-
lar, diagnosis-conﬁrming ﬁndings are ab-
sent. Third, we did not have data on
patient level details of diabetes treatment
(e.g.,typeofinsulinortypeofbloodpres-
sure medication) or dialysis treatment
(e.g.,typeofvascularaccess).Thus,wedo
not exactly know which aspects of treat-
ment improvement have been responsi-
ble for the improved prognosis. On the
other hand, the strength of the study is
that it is based on an exceptionally com-
prehensive nationwide database with
complete coverage of Finnish patients
with ESRD. This excludes selection bias
and allows longer follow-up of patients
with type 1 diabetes receiving RRT than
published before.
Insummary,thesurvivalofFinnishpa-
tients with type 1 diabetes and ESRD has
consistently and signiﬁcantly improved
sincethebeginningofthe1980sdespitethe
progressively older age of patients starting
RRT. During the same time period, survival
in the control group (patients with glomer-
ulonephritis) has also improved but to a
lesser extent. This result indicates a beneﬁ-
cial contribution of both dialysis-related
factors and progress in diabetes care and
highlights the importance of comprehen-
sive diabetes care in patients receiving
chronic renal replacement therapy.
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